ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hospital

Pearls of Wisdom: Innovations in Teaching Shared at the 2022 ACR Education Exchange

  |  

Experts presented ways to rethink journal club to improve engagement and how an image-based program can help teach the assessment of cutaneous lupus erythematosus across differing skin tones.

Summer 2022’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  

Medal for Excellence Awarded to Graciela Alarcón, MD Graciela (Chela) S. Alarcón, MD, MPH, is the emeritus Jane Knight Lowe Chair of Medicine in Rheumatology at the University of Alabama at Birmingham (UAB), and a professor of medicine (emeritus) at Universidad Peruana Cayetano Heredia (UPCH), Lima, Perú, her alma mater. Last fall, she received the…

Gout Experts Share Insights Into a Variety of Challenging Gout Scenarios

  |  

Although the diagnosis and treatment of gout are sometimes straightforward, prac­titioners encounter challenges in patients with atypical presentations, as well as those with medically complex situations or refractory disease. Here, gout experts share insights into some of these scenarios. Flare in Hospitalized Patients When not contraindicated, the 2020 ACR Guideline for the Management of Gout…

We Must Include Diverse Belief Models in Rheumatology Research

Charmayne Dunlop-Thomas, MS, MPH, Nancy Delnay, MSN, APRN-CNP, & the ARP Research Subcommittee  |  

Information overload generated by the media, family, friends and colleagues is apparent today. Personal beliefs play an important role in how we filter and process the abundant information available and subsequently identify its utility in daily life. Regardless of professional specialty, individual beliefs underpin personal approaches to clinical care, research development and engagement with patients…

Rheumatologists & Oculoplastic Surgeons Form Unique Partnership in Oregon

James T. Rosenbaum, MD,* Shravani Mikkilineni, MD, MBA, Hadi Khazaei, MD, Davin C. Ashraf, MD, & John D. Ng, MD, MS, FACS  |  

When my daughter was a second-year internal medicine resident at Massachusetts General Hospital, Boston, she called me excitedly one evening. “Dad,” she reported, “I think I saw the optic nerve for the first time today with an ophthalmoscope.” I suppose I should have shared her exuberance, except that when I went to medical school, a…

Case Report: Abscess as a Manifestation of Autoinflammatory Disease

Katherine Chakrabarti, MD, & Andrew Vreede, MD  |  

Abscesses are typically caused by infections, but some are, instead, sterile. Aseptic abscesses (AAs) are characterized by the same neutrophil-rich histo­pathology as infectious abscesses; however, they don’t improve with antibiotics. Rather, AAs require treatment with anti-inflammatory medications. Although relatively rare, this phenomenon is important for rheumatologists to recognize given its frequent association with under­lying systemic…

Case Report: A Bullous Eruption

Jordan Friedmann, MD, Julia Tan, MD, Danny Mansour, MD, Sheila Au, MD, FRCPC, & Neda Amiri, MD, FRCPC  |  

Eosinophilic granulomatosis with polyangiitis (EGPA) is an anti-neutrophil cytoplasmic antibody-associated vasculitis typically characterized by asthma, peripheral eosinophilia and medium- to small-vessel necrotizing vasculitis. Cutaneous manifes­tations in EGPA are diverse. Palpable purpura is the most common presentation, but urticaria, erythematous macules and papules, livedo reticularis, digital necrosis and cutaneous nodules have also been described.1 Non-hemorrhagic bullae…

Concierge Care: Basketball, Hotels & the Future of Rheumatology

  |  

I wouldn’t normally look to professional basketball as a model for healthcare, but sometimes answers come from unexpected places. The observation that elite athletes are not like you and me—medically speaking—is not new. In the second century AD, the pontifex maximus in Pergamum recognized this fact and appointed Claudius Galen physician to the gladiators, making…

Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising

  |  

In a small preliminary study, the novel MK2 inhibitor, CC-99677, was safe and well tolerated by healthy participants. With daily dosing, the agent sustained reductions of tumor necrosis factor alpha and other cytokines for 14 days.